RPG LIFE SCIENCES share price has plunged 6% and is presently trading at Rs 2,266.5.
Meanwhile, the BSE HEALTHCARE index is at 43,911.1 (up 0.2%).
Among the top losers in the BSE HEALTHCARE index today are GRANULES INDIA (down 2.3%) and SUN PHARMA ADV. RES. (down 2.3%).
HIKAL CHEMIC (up 4.5%) and Natco Pharma (up 4.0%) are among the top gainers today.
Over the last one year, RPG LIFE SCIENCES has moved up from Rs 1,261.4 to Rs 2,266.5, registering a gain of Rs 1,005.1 (up 79.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,436.8 to 43,911.1, registering a gain of 54.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 130.1%), Jubilant Pharmova (up 129.6%) and GRANULES INDIA (up 116.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,606.7 (down 0.4%).
The top losers among the BSE Sensex today are Tata Motors (down 5.8%) and M&M (down 1.6%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.
In the meantime, NSE Nifty is at 24,951.1 (down 0.4%). Tata Motors and ONGC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,127.1 to 81,606.7, registering a gain of 14,479.6 points (up 21.6%).
RPG LIFE SCIENCES net profit grew 21.1% YoY to Rs 268 million for the quarter ended June 2024, compared to a profit of Rs 221 million a year ago. Net sales rose 11.9% to Rs 1,654 million during the period as against Rs 1,478 million in April-June 2023.
For the year ended March 2024, RPG LIFE SCIENCES reported 29.6% increase in net profit to Rs 877 million compared to net profit of Rs 676 million during FY23. Revenue of the company grew 13.5% to Rs 5,821 million during FY24.
The current Price to earnings ratio of RPG LIFE SCIENCES, based on rolling 12 month earnings, stands at 40.6.
Equitymaster requests your view! Post a comment on "RPG LIFE SCIENCES Plunges 6%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!